Zydus Cadila receives USFDA nod for Teriflunomide Tablets

Zydus Cadila has received the final approval for Teriflunomide tablets from the United States of Food and Drug Association (USFDA). Shares of the company could most likely be in limelight on Monday’s trading session.

Teriflunomide tablets, 7 mg and 14mg will be manufactured at the group’s formulations manufacturing unit at SEZ at Ahmedabad. Teriflunomide tablets is used to treat relapsing forms of multiple sclerosis (MS). However the tablet won’t be a complete cure for MS but it would work in decreasing certain immune system cells which could attack the nerve in brain and spinal cord. It would help in decreasing the number of relapses and help to slow down physical problems caused by MS.

On Friday, the shares of the company closed at Rs. 363.90 up by 2.15 per cent or by 7.65 on the BSE. The intraday high was Rs. 365.30 and intraday low was Rs. 353.65 per share on the BSE. Its 52-week high was Rs. 456.10 and 52-week low was Rs. 330.65 per share on the BSE. Meanwhile, BSE Sensex closed at 36,194.30 level, up by 0.07 per cent.